Ortho-McNeil Gets FDA Approval For Complicated Intra-Abdominal/UTI Therapy Doribax
This article was originally published in The Pink Sheet Daily
Executive Summary
Studies of the novel injectable carbapenem antibiotic showed activity in several forms of Gram-positive and Gram-negative bacteria, including Pseudomonas.
You may also be interested in...
FDA Panel Deems Non-inferiority Trials For J&J’s Doribax Inferior
FDA’s Anti-Infective Drugs Advisory votes 10-3 that a 20 percent non-inferiority margin for the antibiotic is not scientifically justifiable.
FDA Panel Deems Non-inferiority Trials For J&J’s Doribax Inferior
FDA’s Anti-Infective Drugs Advisory votes 10-3 that a 20 percent non-inferiority margin for the antibiotic is not scientifically justifiable.
FDA Panel To Weigh Non-Inferiority Trial Margin In Review Of J&J’s Antibiotic Doribax
FDA's Anti-Infective Drugs Advisory Committee will consider the merits of a 20 percent non-inferiority margin based on clinical response in patients with nosocomial and ventilator-associated pneumonia.